Scripta Therapeutics

The company's platform is designed to reprogram diseased cells back to a healthy state by modulating transcription factor activity, moving beyond treating symptoms to addressing the root biological causes. This method challenges conventional target-based drug discovery, which often focuses on a narrow set of well-researched biological mechanisms. Scripta's initial therapeutic focus is on neurodegenerative disorders with significant unmet needs, such as Alzheimer's, Parkinson's, and ALS. However, its technology is biology-agnostic and holds the potential for application in other areas like cancer, fibrosis, and inflammation.

In November 2025, Scripta Therapeutics emerged from stealth, announcing it had secured $12 million in a seed funding round co-led by Oxford Science Enterprises and Apollo Health Ventures, with additional investment from AlbionVC, YZR Capital, and Parkwalk Advisors. The funds are intended to support the expansion of its operations and the development of its discovery platform. The company's business model is centered on developing disease-modifying therapeutics. As part of its growth, experienced biotech leader Ray Barlow was appointed to the board as a Non-Executive Director.